Chronic liver disease type C
Conditions
Interventions
None listed
Sponsors
Department of Hepatology, Osaka City University Graduate School of Medicine
Tokyo University, Yamaguchi University, Osaka University, Osaka Rosai Hospital, Okayama City General Medical Center, Okayama University, Tokushima University, Kagawa Prefectural Central Hospital, Kurume University, Tokai University, Chiba University, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with chronic liver disease related HCV infection
Exclusion criteria
Exclusion criteria: 1) Active malignant tumor including liver cancer 2) Decompensated hepatic cirrhosis 3) Prohibition of per oral drugs 4) Medication contraindication drugs to pan-genotype DAAs 5) Allergy to pan-genotype DAA 6) Unsuitable condition to the present study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained viral response at post-treatment 12-week (SVR12) | — |
Secondary
| Measure | Time frame |
|---|---|
| HCV RNA at end-of-treatment and at post-treatment 24-week (SVR24) Liver function test after treatment Adverse events | — |
Countries
Japan
Contacts
Public ContactAkihiro Tamori
Osaka City University Department of Hepatology
Outcome results
None listed